Neurology and Therapy (Jun 2023)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

  • Tuan Vu,
  • Andreas Meisel,
  • Renato Mantegazza,
  • Djillali Annane,
  • Masahisa Katsuno,
  • Rasha Aguzzi,
  • Ahmed Enayetallah,
  • Kathleen N. Beasley,
  • Nishi Rampal,
  • James F. Howard

DOI
https://doi.org/10.1007/s40120-023-00514-4
Journal volume & issue
Vol. 12, no. 5
pp. 1435 – 1438

Abstract

Read online

Abstract This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis (MP4 594600 KB)

Keywords